Rosette‑Forming Glioneuronal Tumor (RGNT)

Overview

Rosette‑forming glioneuronal tumor (RGNT) is a rare, low‑grade (World Health Organization grade I) brain tumor that contains both glial (supporting) and neuronal (nerve) components arranged in characteristic “rosette” patterns under the microscope. It most frequently arises in the fourth ventricle and nearby brainstem structures, but can also occur in the cerebellum, spinal cord, or supratentorial regions.

• Typical age: Median age at diagnosis is 20–30 years, but cases range from early childhood to late adulthood.
• Gender: Slight female predominance (≈55 % female).
• Prevalence: RGNT accounts for < 0.5 % of all primary central nervous system tumors. Large registry data (CBTRUS, 2020) report about 300‑400 cases worldwide, reflecting its rarity.
• Behavior: Generally indolent with slow growth, but can cause significant symptoms due to its location near vital brain structures.

Symptoms

Because RGNT grows in confined spaces of the posterior fossa, symptoms often relate to obstruction of cerebrospinal fluid (CSF) flow or compression of nearby nuclei. The clinical picture varies, but common features include:

Headache

• Pressure‑type headache that worsens in the morning or with Valsalva maneuvers (coughing, bending).
• May be accompanied by nausea and vomiting.

Nausea & Vomiting

• Usually nocturnal or early‑morning, indicating increased intracranial pressure (ICP).

Balance & Coordination Problems

• Unsteady gait, difficulty walking on uneven surfaces.
• Fine‑motor clumsiness (dysmetria) due to cerebellar involvement.

Vertigo & Dizziness

• Sensation of spinning or light‑headedness, often triggered by head movement.

Visual Disturbances

• Double vision (diplopia) from cranial nerve VI palsy or brainstem compression.
• Blurred vision if hydrocephalus affects optic pathways.

Facial Nerve or Bulbar Symptoms

• Weakness or numbness on one side of the face.
• Difficulty swallowing, slurred speech, or coughing with liquids.

Seizures

• Rare, but may occur when tumors are located supratentorially.

Cognitive & Mood Changes

• Memory lapses, concentration difficulty, or irritability, especially in larger lesions.

Hydrocephalus‑Specific Signs

• Enlarged head circumference in children.
• Papilledema (swelling of optic disc) seen on eye exam.

Causes and Risk Factors

RGNT is not linked to a known environmental cause or inherited syndrome. Current research suggests the following:

• Genetic alterations: Whole‑exome sequencing has identified recurrent mutations in the FGFR1 gene and occasional alterations in PIK3CA. These affect signaling pathways that regulate cell growth, but their role in tumor initiation remains under investigation.¹
• Age: The tumor’s peak incidence in young adults suggests developmental factors may contribute.
• Sex: Slight female predilection, though the reason is unclear.
• Prior radiation: No strong evidence, but radiation exposure is a known risk for other low‑grade gliomas.
• Family history: No hereditary pattern has been established; routine genetic counseling is not generally indicated.

Diagnosis

Diagnosing RGNT requires a combination of clinical assessment, imaging, and histopathology.

Neuro‑Imaging

• Magnetic Resonance Imaging (MRI): The gold standard. Typical findings:
  • Well‑circumscribed, mixed solid‑cystic lesion in the fourth ventricle or adjacent brainstem.
  • Iso‑ to mildly hypointense on T1‑weighted images, hyperintense on T2/FLAIR.
  • Variable contrast enhancement (often minimal or peripheral).
  • Absence of diffusion restriction, distinguishing it from high‑grade tumors.
• CT scan: May show calcifications or bone remodeling but is less sensitive than MRI.
• MR Spectroscopy: Usually shows low choline and normal N‑acetyl‑aspartate, supporting a low‑grade lesion.

Biopsy / Surgical Resection

Definitive diagnosis hinges on microscopic examination:

• Rosette structures: True rosettes with a central lumen surrounded by tumor cells.
• Perivascular pseudorosettes: Tumor cells arranged around blood vessels.
• Immunohistochemistry: Positivity for neuronal markers (NeuN, Synaptophysin) and glial markers (GFAP).

Additional Tests

• Neurological exam to document deficits.
• Baseline ophthalmologic exam for papilledema.
• Baseline neurocognitive testing if the tumor is near eloquent cortex.

Treatment Options

Given their low‑grade nature, treatment aims to relieve mass effect, prevent hydrocephalus, and achieve long‑term control while preserving neurological function.

Surgical Management

• Gross‑Total Resection (GTR): Preferred when safely achievable. Studies report >90 % progression‑free survival at 5 years after GTR.²
• Sub‑total Resection (STR) or Biopsy: Considered when the tumor is adherent to vital brainstem structures. May be followed by close imaging surveillance.
• Endoscopic third ventriculostomy (ETV) or ventriculoperitoneal (VP) shunt: Used to treat obstructive hydrocephalus.

Radiation Therapy

• Reserved for recurrent or residual tumor that cannot be re‑operated.
• Low‑dose focal radiotherapy (54 Gy in 30 fractions) has been employed with modest control rates.
• Potential long‑term risks (cognitive decline, secondary malignancy) are weighed carefully, especially in younger patients.

Chemotherapy

There is no standard chemotherapeutic regimen for RGNT because of its indolent behavior. Temozolomide or carboplatin‑based protocols have been tried in isolated case reports with limited benefit.

Targeted Therapy & Clinical Trials

• FGFR1 inhibitors (e.g., erdafitinib) are under early investigation for tumors harboring FGFR1 mutations.³
• Patients should be referred to tertiary centers for trial eligibility.

Supportive & Lifestyle Measures

• Analgesics for headache (acetaminophen, NSAIDs) – use with caution in patients with hydrocephalus.
• Antiemetics (ondansetron) for nausea.
• Physical therapy to improve balance and coordination after surgery.
• Regular ophthalmology follow‑up for papilledema.

Living with Rosette‑Forming Glioneuronal Tumor

While RGNT is often curable or controllable, long‑term follow‑up and lifestyle adjustments are essential.

Follow‑up Schedule

• Post‑operative MRI at 3 months, then every 6–12 months for the first 5 years.
• Annual MRI after 5 years if stable.
• Neuro‑ophthalmology exam annually or sooner if visual symptoms develop.

Managing Daily Symptoms

• Headache control: Keep a headache diary; identify triggers (caffeine, lack of sleep) and discuss prophylactic options with a neurologist.
• Balance training: Vestibular rehabilitation exercises can reduce dizziness and improve gait.
• Fatigue management: Schedule rest periods, maintain regular sleep hygiene.
• Emotional well‑being: Consider counseling or support groups; anxiety and depression are common after brain tumor diagnosis.

Rehabilitation

• Physical therapy for strength and gait.
• Occupational therapy to adapt to fine‑motor deficits.
• Speech‑language therapy if bulbar symptoms persist.

Work & School

• Discuss accommodations with employers or schools (extra time for tasks, flexible scheduling).
• If cognitive deficits are noted, neuropsychological evaluation can guide educational strategies.

Healthy Lifestyle

• Balanced diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• Regular moderate‑intensity aerobic exercise (e.g., walking, swimming) as tolerated.
• Avoid smoking and limit alcohol, which can impair recovery and increase vascular risk.

Prevention

Because the exact cause of RGNT is unknown, specific primary prevention is not possible. General measures that support brain health may be beneficial:

• Maintain a healthy vascular profile (control blood pressure, cholesterol, diabetes).
• Limit exposure to ionizing radiation when medically unnecessary.
• Adopt a lifestyle that reduces chronic inflammation (diet, exercise, stress management).
• For individuals with a family history of rare CNS tumors, consider genetic counseling, although evidence linking heredity to RGNT is minimal.

Complications

If left untreated or incompletely treated, RGNT can lead to:

• Obstructive hydrocephalus: Increased ICP → headache, vomiting, vision loss, herniation (medical emergency).
• Brainstem compression: Dysphagia, respiratory compromise, cranial nerve deficits.
• Progressive ataxia: Falls and injury due to worsening balance.
• Seizures: Particularly with supratentorial extension.
• Secondary malignancy: Rare, but radiation exposure can increase long‑term risk.
• Neurocognitive decline: From tumor mass effect, hydrocephalus, or treatment‑related factors.

When to Seek Emergency Care

---

**References**

1. Suárez‑García O et al. Molecular genetics of rosette‑forming glioneuronal tumors. *Neuro‑Oncology* 2020.
2. Cleveland Clinic. Glioneuronal Tumors: Diagnosis and Management.
3. Korshunov A et al. Targetable FGFR1 alterations in low‑grade CNS neoplasms. *Journal of Clinical Oncology* 2020.
4. Mayo Clinic – Brain Tumor
5. CDC – Brain and Other CNS Cancers
6. National Cancer Institute – Brain Tumors
7. WHO – Cancer Fact Sheets